已发表论文

化疗期间卵巢癌患者复发恐惧与睡眠障碍的网络分析

 

Authors Wu Y, Zhang Y, Zhang L , Yang J, Zhu W, Xu C

Received 25 August 2025

Accepted for publication 29 November 2025

Published 9 December 2025 Volume 2025:17 Pages 5259—5268

DOI https://doi.org/10.2147/IJWH.S563088

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 4

Editor who approved publication: Dr Everett Magann

Yaru Wu,1 Yuting Zhang,1 Li Zhang,1 Juan Yang,1 Wei Zhu,2,3 Chunyan Xu2,3 

1School of Nursing, Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China; 2Department of Gynecological Surgery, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang, People’s Republic of China; 3Health Care Research Center for Xinjiang Regional Population, Urumqi, Xinjiang, People’s Republic of China

Correspondence: Chunyan Xu, Email xcy101413@163.com

Background: This quantitative study aimed to analyze the internal association mechanism between the core symptoms of fear of recurrence and sleep disturbances among ovarian cancer chemotherapy patients in Western Region of China.
Methods: From October 2024 to July 2025, a convenience sampling method was used to administer a questionnaire to ovarian cancer chemotherapy patients at a gynecology center within a university hospital situated in the Northwest region of China. The investigation employed general information questionnaires, Pittsburgh Sleep Quality Index (PSQI) and Fear of Cancer Recurrence-Short Form (FCR-Q-SF) to conduct the survey. Use R language to construct a network visual map, calculate centrality indicators, and describe the relationships among symptoms.
Results: This study included a total of 248 patients with ovarian cancer undergoing chemotherapy. The incidence rates of fear of recurrence and sleep disorders were 54.3% and 66.2%, respectively. Univariate analysis showed a positive correlation between patients’ fear of cancer recurrence and sleep disorders (P< 0.05). The core symptom in the fear of cancer recurrence network is “F10 worrying that medications will harm my body”. The bridging node connecting symptoms across different dimensions is “F11 worrying about what will happen to my family if something happens to me”. In the network of fear of recurrence and sleep disorders, the core symptoms are “F10 worrying that medications will harm my body”, “S1 sleep latency”, and “S6 sleep problems” in sequence. Additionally, “sleep problems” serves as the bridging node connecting symptoms of fear of recurrence and sleep disorders.
Conclusion: The network structure of disease symptoms helps to gain an in-depth understanding of the mechanism of fear of cancer recurrence and its relationship with sleep disorders in ovarian cancer patients. Based on this, it is recommended that clinical practitioners prioritize the prevention and alleviation of patients’ anxiety about medication-induced harm, and strengthen attention to sleep problems, so as to better improve their overall mental health.

Keywords: ovarian cancer, fear of recurrence, sleep disorders, network analysis